ImageBiopsy Lab ImageBiopsy Lab, operated by Vienna-based IB Lab GmbH, develops AI software that analyzes musculoskeletal medical images for radiologists and orthopedic clinicians. Its modular IB Lab ZOO platform integrates with PACS and RIS systems and returns standardized measurements and reports from X-rays and CT images. Applications include knee osteoarthritis assessment, pediatric bone-age estimation, lower-limb alignment and hip measurements, scoliosis assessment, and opportunistic screening for vertebral fractures and low bone mineral density. Its portfolio supports bone-health screening, diagnosis, surgical planning and follow-up, including analysis around hip and knee implants. The FDA has cleared its KOALA knee-analysis software and IB Lab LAMA leg-measurement software; regulatory status is specific to the product and market. Founded in 2016, the company has its headquarters in Vienna and publishes a separate US subsidiary, ImageBiopsy Lab, Inc., in New Jersey.
Founded 2016
Philip Meier Co-Founder; Chief Commercial Officer (issuer article, March 2022) Richard Ljuhar Founder, Chief Innovation Officer and Chief Commercial Officer
SHOW MORE
team@apexlogos.ai · 16 hours ago
Identity verified October 7, 2026: brand ImageBiopsy Lab is operated by IB Lab GmbH, FN461415b, Zehetnergasse 6/2/2, 1140 Vienna. The separate US company ImageBiopsy Lab, Inc. has an office at 575 Route 28, Building 2, Suite 2200, Raritan, NJ 08869; this profile represents the Austrian issuer, not a merger of legal entities. Founded 2016 is issuer-confirmed. Current own executive directory lists Reinhard Krickl CEO; Richard Ljuhar founder, CIO/CCO; Christoph Götz co-founder/COO; Zsolt Bertalan CTO; Günter K. Angel CFO. Philip Meier is an issuer-confirmed founder and dated March 1, 2022 CCO; no current CCO appointment is inferred. The Advisory navigation anchor has no named current adviser directory; testimonials from clinicians are not staff appointments. Existing ReinhardKrickl personal and other organization/investment data is preserved. Current logo comes from July 1, 2026 rebrand. FDA exact clearances: KOALA K192109 decision November 5, 2019 and IB Lab LAMA K223646 decision June 16, 2023, applicant IB Lab GmbH; no blanket FDA clearance for every ZOO module. Rho by 16 Bit and RBfracture are explicitly partner solutions, not separate owned startups. UCB BoneBot licensing is a commercial/development partnership, not an inferred equity investment. Current own investor gallery and actual ILUM/APEX/aws portfolio pages confirm four investor relations including IT-Farm. Four separate investor-specific holding milestones carry these links, each with unknown amount, date, stage, ticket, lead and fund allocation. They do not assert four known cash financings or one shared co-financing event; each source establishes only its respective holding relationship. Issuer-supplied 2019 LISAvienna release says APEX and aws have been on board since December 2018; no exact day or amount is disclosed there. Aggregators give conflicting May 2020 USD 2m versus EUR 1.85m/1.9m, and July 1 versus July 31, 2023 Series A/Series A2. Those claims are not written as exact rounds without primary corroboration. Neither accelerators nor public seedfinancing grants are treated as equity rounds. Sources: https://imagebiopsy.com/legals/legal-notice https://imagebiopsy.com/about-us https://www.imagebiopsy.com/ https://imagebiopsy.com/products https://imagebiopsy.com/blog-posts/introducing-the-new-imagebiopsy-lab-ai-solutions-for-bone-health-from-prevention-to-surgery https://www.imagebiopsy.com/blog-posts/imagebiopsy-lab-ceo-richard-ljuhar-named-innovator-of-the-year-2023 https://www.imagebiopsy.com/blog-posts/i-think-ai-certainly-help-take-a-look-at-the-volume-of-imaging-coming-in-and-help-triage-it-post-image-acquisition-if-you-will https://api.fda.gov/device/510k.json?search=applicant%3A%22Ib%20Lab%20GmbH%22&limit=100 https://ilumtec.at/en/ https://www.apex.ventures/portfolio/image-biopsy-lab https://www.gruendungsfonds.at/portfolio https://www.lisavienna.at/news/detail/imagebiopsy-lab-and-leiden-university-medical-center-partnership-to-create-value-based-ai-diagnostic/ https://www.fcf.de/wp-content/uploads/2023-08-04-FCF-Healthcare-Life-Sciences-Venture-Capital-Monitor-Europe-07-2023.pdf SHOW MORE
